This article was downloaded by: [FU Berlin] On: 11 May 2015, At: 11:14 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



# Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lsyc20

# Improved Synthesis of (-)-Agelastatin A

Franklin A. Davis  $^{a}$  , Junyi Zhang  $^{a}$  , Yanfeng Zhang  $^{a}$  & Hui Qiu  $^{a}$ 

<sup>a</sup> Department of Chemistry, Temple University, Philadelphia, Pennsylvania, USA Published online: 27 Apr 2009.

To cite this article: Franklin A. Davis , Junyi Zhang , Yanfeng Zhang & Hui Qiu (2009) Improved Synthesis of (-)-Agelastatin A, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 39:11, 1914-1919, DOI: <u>10.1080/00397910802618885</u>

To link to this article: <u>http://dx.doi.org/10.1080/00397910802618885</u>

# PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or

indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions *Synthetic Communications*<sup>®</sup>, 39: 1914–1919, 2009 Copyright © Taylor & Francis Group, LLC ISSN: 0039-7911 print/1532-2432 online DOI: 10.1080/00397910802618885



## Improved Synthesis of (–)-Agelastatin A

Franklin A. Davis, Junyi Zhang, Yanfeng Zhang, and Hui Qiu

Department of Chemistry, Temple University, Philadelphia, Pennsylvania, USA

Abstract: Optimization of key steps in the synthesis of the architecturally unique tetracyclic antitumor alkaloid (–)-agelastatin A (1) improved the overall yield of the 11-step process (eight operations) from 9% to 23%. Changing the solvent and using a more efficient *N*-benzyl deprotecting-group procedure enhanced the yields of the C-ring and D-ring intermediates, (–)-4 and (–)-7, respectively. Bromination of (–)-7 with 1,3-dibromo-5,5-dimethylhydantoin, rather than *N*-bromosuccinimide (NBS), increased the yield of (–)-1 from 69% to more than 94% yield.

Keywords: (-)-Agelastatin A, 1,3-dibromo-5,5-dimethylhydantoin, Michael addition

Recently we described a concise asymmetric synthesis of (–)-agelastatin A (1) from the key C-ring intermediate 4,5-diamino cyclopenten-2-enone (–)-2 (Scheme 1).<sup>[1,2]</sup> Compound 2 was efficiently prepared from the sulfinimine-derived (–)-2,3-diamino ester 3 using ring-closing metathesis. (–)-Agelastatin A (1) is an architecturally unique cytotoxic tetracyclic alkaloid isolated from the marine sponge *Agelas dedromorpha*.<sup>[3]</sup> It is reported to be active against a number of tumor cell lines, and it inhibits glycogen synthase kinase- $3\beta$ .<sup>[4]</sup> Although our synthesis of (–)-1 is the most efficient one to date, 11 steps under eight operations (9% overall yield), there were several steps that proceeded in modest or low yields. We describe here an improved synthesis of (–)-1, 11 steps under eight operations (23% overall yield), with a 10-fold increase in scale.

Received August 22, 2008.

Address correspondence to Franklin A. Davis, Department of Chemistry, Temple University, Philadelphia, PA 19122. E-mail: fdavis@temple.edu



Scheme 1. Retro-synthetic analysis of (-)-agelastatin A.

Our improved synthesis begins with 4,5-diamino cyclopenten-2-enone (1R,5S)-(-)-2, which was prepared in six steps (four operations) from (-)-3 in 58% overall yield as previously described.<sup>[1]</sup> 2,3-Diamino ester (-)-3 was prepared by addition of the lithium enolate of ethyl (dibenzylamino)acetate to an acrolein-derived sulfinimine in 73% yield. Experimental details for the synthesis of (-)-2 can be found in Ref. 1. Weinreb and coworkers had earlier reported the synthesis of the C-ring intermediate by an intramolecular Michael cyclization using  $Cs_2CO_3/$ MeOH.<sup>[2a]</sup> By applying this procedure with 10 equivalents of  $Cs_2CO_3/$ MeOH, we obtained (-)-4 in 68% yield, but control of the reaction time was critical (Table 1, entry 1). It was found that reaction times longer than 16 min resulted in formation of the retro-Michael product cyclopentenone (R)-(-)-5 and decomposition products (Table 1, entry 2). By switching the solvent to tetrahydrofuran (THF), the reaction was much slower, and it was possible to avoid formation of (-)-5 (Scheme 2). However, it was only possible to push the reaction yield to 66% with recovery of 26% of (-)-2. Increasing the reaction time failed to improve the yield of (-)-4, and decomposition products were observed (Table 1, entry 4). When recovered (-)-2 was subjected to the reaction conditions, an additional 15% of (-)-4 was isolated for a combined yield of 81%.

Formation of (–)-debromoagelastatin A (7) requires removal of the *N*-benzyl protecting groups in (–)-4 to give the  $\alpha$ -amino ketone 6, which is reacted with methyl isocyanate to give the D-ring (Scheme 3).



Scheme 2. Synthesis of the C-ring intermediate.

Entry	Solvent	Time (h)	Products (% isolated yield)
1 2 3 4	MeOH THF	0.27 2 2 4	(-)-4 (68); $(-)-5$ (trace) (-)-4 (0); $(-)-5$ (46) <sup><i>a</i></sup> (-)-4 (66); $(-)-2$ (26) (-)-4 (66): $(-)-2$ (20) <sup><i>a</i></sup>

Table 1. Conversion of (-)-2 to (-)-4 using 10 equiv of Cs<sub>2</sub>CO<sub>3</sub>

<sup>a</sup>Decomposition products observed.

However,  $\alpha$ -amino ketones are notoriously unstable and rapidly epimerize and self-condense.<sup>[5]</sup> This was avoided by removal of the benzyl protecting groups (10% Pd-C, H<sub>2</sub>) in the presence of methyl isocyanate, thereby trapping the amino ketone **6** (Scheme 3).<sup>[1]</sup> Unfortunately, in addition to the desired (–)-debromoagelastatin A (7), *N*-benzyl debromoagelastatin A (**8**) was also produced in significant amounts. All attempts to remove the *N*-benzyl group in **8** proved unsuccessful. Reasoning that the problem was incomplete debenzylation of (–)-**4**, we switched to 30% Pd-C and increased the amount to 6.5 equivalents. This resulted in an isolated yield of 70% (–)-**7** and 8% **8** being formed (Scheme 3).



Scheme 3. Synthesis of the D-ring intermediate and (-)-agelastatin A.

Bromination of (-)-7 using N-bromosuccinimide (NBS) according to Feldman's protocol originally afforded (-)-1 in 69% yield.<sup>[1,2c]</sup> However, when the bromination was conducted with 1,3-dibromo-5,5-dimethylhydantoin (9) in MeOH-THF, the yield rose to 94% (Scheme 3).

In summary, an improved synthesis of the novel marine alkaloid (–)agelastatin A (1) has been accomplished by employing THF to optimize the Michael addition reaction, (–)-2 to (–)-4, increasing the efficiency of the *N*-benzyl deprotection step, by using excess 30% Pd-C, (–)-4 to (–)-7, and employing 9 to brominate (–)-7. The result was 11 steps (eight operations) with an overall yield of 23% from the sulfinimine.

#### EXPERIMENTAL

N-(-)-[(1R,5S)-5-(Dibenzylamino)-4-oxocyclopent-2-enyl)]-1H-pyrrole-2-carboxamide (2) was prepared as previously described.<sup>[1]</sup>

#### (-)-**Pyrrole** (4)

In a 250-mL, single-necked, round-bottomed flask equipped with a magnetic stirring bar, rubber septum, and argon balloon, (-)-2 (0.64 g, 1.68 mmol) and  $Cs_2CO_3$  (5.48 g, 16.8 mmol) in THF (60 mL) were placed. The solution was stirred at rt for 2h before it was filtered and concentrated. Chromatography (hexanes-EtOAc, 1:1) gave 0.16 g of (-)-2 and 0.42 g (66%) of (-)-4. Cs<sub>2</sub>CO<sub>3</sub> (1.37 g, 4.2 mmol) was added to the solution of recovered (-)-2 (0.16, 0.42 mmol) in THF (15 mL), and the reaction mixture was stirred at rt for 2 h. At this time, the solution was filtered and concentrated, and chromatography (hexanes-EtOAc, 1:1) gave 0.096 g (15%) of an off-white solid. Combined (-)-4, 0.52 g (81\%) yield; mp 195.5°C (lit.<sup>[1]</sup> mp 195°C);  $[\alpha]^{20}_{D} = -10.5$  (c 0.3, CHCl<sub>3</sub>) [lit.<sup>[1]</sup> = -10.2 (c 0.28, CHCl<sub>3</sub>)]; IR (neat): 3854, 1653, 1350 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  2.64 (dd, J = 6.0 Hz, J = 19.2 Hz, 1 H), 3.0 (d, J = 19.2 Hz, 1 H), 3.49 (d, J = 10.5 Hz, 1 H), 3.88 (m, 1 H), 3.94 (s, 4 H), 4.68 (t, J = 6.0 Hz, 1 H), 6.27 (m, 1 H), 6.45 (d, J = 3.0 Hz, 1 H), 6.71 (m, 1 H), 6.91 (m, 1 H), 7.24–7.4 (m, 10 H); <sup>13</sup>C NMR δ 43.0, 50.4, 54.6, 56.5, 70.0, 111.3, 115.4, 122.4, 123.8, 127.9, 128.9, 138.9, 158.9, 211.3. The spectral data are consistent with literature values.<sup>[1]</sup>

## (-)-Debromoagelastatin A (7)

In a 50-mL, two-necked, round-bottomed flask equipped with a magnetic stirring bar, rubber septum, and hydrogen balloon, (-)-4 (0.266 g,

0.69 mmol) and 30% Pd/C (1.33 g, 3.75 mmol) in THF (25 mL) were placed, and methyl isocyanate (0.407 mL, 6.9 mmol) was quickly added. After 12 h, the catalyst was filtered, and the filtrate was concentrated. Chromatography (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) gave 0.019 g (8%) of (-)-**8**<sup>[1]</sup> and 0.108 g (70%) of (-)-7 as an off-white solid, mp 244.0–244.5°C (lit<sup>[11]</sup> mp 244–245°C);  $[\alpha]^{20}{}_{D} = -67.2$  (*c* 0.4, MeOH) [lit.<sup>[11]</sup>  $[\alpha]^{20}{}_{D} = -66.2$  (*c* 0.21, MeOH)]. IR (neat): 3281, 2849, 1653, 1559 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OH)  $\delta$  2.27 (dd, J = 10.5 Hz, J = 12.9 Hz, 1 H), 2.55–2.54 (m, 1 H), 2.78 (s, 3 H), 3.79 (s, 1 H), 3.98 (d, J = 5.4 Hz, 1 H), 4.6–4.67 (m, 1 H), 6.21 (t, J = 5.4, 1 H), 6.87 (d, J = 3.9 Hz, 1 H), 7.01–7.2 (m, 1 H); <sup>13</sup>C NMR  $\delta$  24.2, 41.6, 55.6, 62.8, 68.0, 95.8, 111.0, 115.4, 122.9, 125.6, 161.3, 162.0. The spectra data are consistent with literature values.<sup>[1]</sup>

#### (-)-Agelastatin A (1)

In a 25-mL, one-necked, round-bottomed flask equipped with a magnetic stirring bar, rubber septum, and argon balloon, MeOH (5 mL), THF (10 mL), (–)-7 (0.026 g, 0.1 mmol) were placed. The solution was cooled to – 78°C, and 1,3-dibromo-5,5-dimethylhydantoin (9) (0.014 g, 0.049 mmol) was added. The reaction mixture was stirred at this temperature for 2 h, warmed to rt, and stirred for 12 h. At this time, the solution was concentrated and purified by preparative thin-layer chromatography (TLC) (1:4 MeOH/EtOAC) to give 0.032 g (94%) of an off-white solid;  $[\alpha]^{20}{}_{\rm D}$  = – 60.8 (*c* 0.35, MeOH) [lit.<sup>[11]</sup>–62.2 (*c* 0.18, MeOH)]; the compound decomposed at 180°C; IR (neat): 3289, 2917, 1657, 1564 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  2.08 (t, *J*=12.9 Hz, 1 H), 2.62 (dd, *J*=6.3 Hz, *J*=13.2 Hz, 1 H), 2.79 (s, 3H), 3.87 (s, 1 H), 4.06 (*J*=5.7 Hz, 1 H), 4.58 (m, 1 H), 6.30 (*J*=3.9 Hz, 1 H), 6.89 (*J*=3.9 Hz, 1 H); <sup>13</sup>C NMR 24.6, 40.4, 54.8, 62.6, 67.8, 96.1, 107.6, 114.2, 116.4, 124.5, 161.5, 161.8. The spectral data are consistent with literature values.<sup>[11]</sup>

### ACKNOWLEDGMENT

This work was supported by the National Institute of General Medical Sciences (GM 51982 and 57870).

### REFERENCES

- Davis, F. A.; Deng, J. Asymmetric total synthesis of (-)-agelastatin A using sulfinimine (N-sulfinyl imine) derived methodologies. Org. Lett. 2005, 7, 621–623.
- 2. For synthesis of **1** and related compounds, see (a) Stein, D.; Anderson, G. T.; Chase, C. E.; Koh, Y.-H.; Weinreb, S. M. Total synthesis of the antitumor

marine sponge alkaloid agelastatin A. J. Am. Chem. Soc. **1999**, *121*, 9574– 9579; (b) Anderson, G. T.; Chase, C. E.; Koh, Y.-H.; Stein, D.; Weinreb, S. M. Studies on total synthesis of the cytotoxic marine alkaloid agelastatin A. J. Org. Chem. **1998**, 63, 7594–7595; (c) Feldman, K. S.; Saunders, J. C. Alkynyliodonium salts in organic synthesis: Application to the total synthesis of (–)-agelastatin A and (–)-agelastatin B. J. Am. Chem. Soc. **2002**, *124*, 9060– 9061; (d) Feldman, K. S.; Saunders, J. C.; Wrobleski, M. L. Alkynyliodonium salts in organic synthesis: Development of a unified strategy for the syntheses of (–)-agelastatin A and (–)-agelastatin B. J. Org. Chem. **2002**, *67*, 7096–7109; (e) Domostoj, M. M.; Irving, E.; Scheinmann, F.; Hale, K. J. New total synthesis of the marine antitumor alkaloid (–)-agelastatin A. Org. Lett. **2004**, *6*, 2615–2618; (f) Trost, B. M.; Dong, G. New class of nucleophiles for palladium-catalyzed asymmetric allylic alkylation. Total synthesis of agelastatin A. J. Am. Chem. Soc. **2006**, *128*, 6054–6055.

- (a) D'Ambrosio, M.; Guerriero, A.; Debitus, C.; Ribes, O.; Pusset, J.; Leroy, S.; Pietra, F. Agelastatin A, a new skeleton cytotoxic alkaloid of the oroidin family: Isolation from the axinellid sponge *Agelas dendromorpha* of the coral sea. J. Chem. Soc., Chem. Commun. 1993, 1305–1306; (b) D'Ambrosio, M.; Guerriero, A.; Chiasera, G.; Pietra, F. Conformational preferences and absolute configuration of agelastatin A, a cytotoxic alkaloid of the axinellid sponge *Agelas dendromorpha* from the Coral Sea, via combined molecular modeling, NMR, and exciton splitting for diamide and hydroxyamide derivatives. *Helv. Chim. Acta* 1994, *77*, 1895–1902.
- For a review of the synthesis and mechanisms of action of (-)-1, see: Hale, K. J.; Domostoj, M. M. Total synthesis and mechanism of action studies on the antitumor alkaloid, (-)-agelastatin A. *Strat. Tactics Org. Synth.*, 2005, 6, 352–394.
- For leading references, see (a) Davis, F. A.; Ramachandar, T.; Liu, H. Asymmetric synthesis of α-amino 1,3-dithioketals from sulfinimines (*N*-sulfinyl imines): Synthesis of (2*S*,3*R*)-(-)-3-hydroxy-3-methylproline. Org. Lett. 2004, 6, 3393–3395; (b) Davis, F. A.; Ramachandar, T.; Chai, J.; Skucas, E. Asymmetric synthesis of (-amino aldehydes from sulfinimine (*N*-sulfinylimine)-derived α-amino 1,3-dithianes: Formal synthesis of (-)-2,3-trans-3,4-cis-dihydroxyproline. Tetrahedron Lett. 2006, 47, 2743–2746.